Linked Life Data

3118413

Source:http://linkedlifedata.com/resource/pubmed/id/3118413

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1987-11-27
pubmed:abstractText
We investigated the effects of a new pyridoquinazoline thromboxane synthetase inhibitor infused before administering Escherichia Coli endotoxin into 18 anesthetized sheep with lung lymph fistulas. In normal sheep increasing plasma Ro 23-3423 concentrations were associated with increased plasma levels of 6-keto-PGF1 alpha, a reduced systemic vascular resistance (SVR, r = -0.80) and systemic arterial pressure (SAP, r = -0.92), the mean SAP falling from 80 to 50 mm Hg at the 20 and 30 mg/kg doses. Endotoxin infused into normal sheep caused transient pulmonary vasoconstriction associated with increased TxB2 and 6-keto-PGF1 alpha levels while vasoconstriction and TxB2 increase were significantly inhibited by pretreatment with Ro 23-3423 in a dose-dependent manner. When compared to controls, plasma and lymph levels of 6-keto-PGF1 alpha, PGF2 alpha and PGE2 after endotoxin infusion were increased several-fold by administering Ro 23-3423 up to plasma levels of 10 micrograms/ml. Doses over 30 mg/kg with blood levels above 10 micrograms/ml reduced plasma and lymph levels of 6-keto-PGF1 alpha, PGF2 alpha and PGE2, suggesting cyclooxygenase blockade at this dose. The peak 6-keto-PGF1 alpha levels at 60 min after endotoxin infusion in sheep with Ro-23-3423 levels below 10 micrograms/ml were associated with the greatest systemic hypotension due to a reduced SVR (r = -0.86). After endotoxin infusion the leukotrienes B4, C4, D4 and E4 in lung lymph were assayed by radioimmunoassay and high pressure liquid chromatography and remained at baseline values.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0090-6980
pubmed:author
pubmed:issnType
Print
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
879-902
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:3118413-6-Ketoprostaglandin F1 alpha, pubmed-meshheading:3118413-Animals, pubmed-meshheading:3118413-Arachidonic Acid, pubmed-meshheading:3118413-Arachidonic Acids, pubmed-meshheading:3118413-Blood Pressure, pubmed-meshheading:3118413-Dinoprostone, pubmed-meshheading:3118413-Endotoxins, pubmed-meshheading:3118413-Escherichia coli, pubmed-meshheading:3118413-Hemodynamics, pubmed-meshheading:3118413-Kinetics, pubmed-meshheading:3118413-Lymph, pubmed-meshheading:3118413-Prostaglandins E, pubmed-meshheading:3118413-Prostaglandins F, pubmed-meshheading:3118413-Pulmonary Artery, pubmed-meshheading:3118413-Quinazolines, pubmed-meshheading:3118413-Sheep, pubmed-meshheading:3118413-Thromboxane B2, pubmed-meshheading:3118413-Thromboxane-A Synthase, pubmed-meshheading:3118413-Toxemia, pubmed-meshheading:3118413-Vascular Resistance
pubmed:year
1987
pubmed:articleTitle
Dose-dependent effects of a pyridoquinazoline thromboxane synthetase inhibitor on arachidonic acid metabolites and hemodynamics during E. coli endotoxemia in anesthetized sheep.
pubmed:affiliation
Department of Anesthesia, Massachusetts General Hospital, Boston 02114.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't